JAZZ logo

Jazz Pharmaceuticals plc (JAZZ) EBITDA

Annual EBITDA:

$1.39B+$88.72M(+6.84%)
December 31, 2024

Summary

  • As of today, JAZZ annual EBITDA is $1.39 billion, with the most recent change of +$88.72 million (+6.84%) on December 31, 2024.
  • During the last 3 years, JAZZ annual EBITDA has risen by +$434.94 million (+45.70%).
  • JAZZ annual EBITDA is now at all-time high.

Performance

JAZZ EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherJAZZincome statement metrics

Quarterly EBITDA:

$339.75M-$53.22M(-13.54%)
September 30, 2025

Summary

  • As of today, JAZZ quarterly EBITDA is $339.75 million, with the most recent change of -$53.22 million (-13.54%) on September 30, 2025.
  • Over the past year, JAZZ quarterly EBITDA has dropped by -$85.69 million (-20.14%).
  • JAZZ quarterly EBITDA is now -20.14% below its all-time high of $425.44 million, reached on September 30, 2024.

Performance

JAZZ Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherJAZZincome statement metrics

TTM EBITDA:

$1.20B-$85.69M(-6.66%)
September 30, 2025

Summary

  • As of today, JAZZ TTM EBITDA is $1.20 billion, with the most recent change of -$85.69 million (-6.66%) on September 30, 2025.
  • Over the past year, JAZZ TTM EBITDA has dropped by -$188.03 million (-13.54%).
  • JAZZ TTM EBITDA is now -13.54% below its all-time high of $1.39 billion, reached on September 30, 2024.

Performance

JAZZ TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherJAZZincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

JAZZ EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+6.8%-20.1%-13.5%
3Y3 Years+45.7%+11.2%+2.1%
5Y5 Years+37.0%+22.4%+19.9%

JAZZ EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+45.7%-20.1%+211.8%-13.5%+3.2%
5Y5-Yearat high+45.7%-20.1%+211.8%-13.5%+27.3%
All-TimeAll-Timeat high+1235.9%-20.1%+405.4%-13.5%+823.7%

JAZZ EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
$339.75M(-13.5%)
$1.20B(-6.7%)
Jun 2025
-
$392.98M(+260.6%)
$1.29B(+2.4%)
Mar 2025
-
$108.98M(-69.7%)
$1.26B(-9.4%)
Dec 2024
$1.39B(+6.8%)
$359.19M(-15.6%)
$1.39B(-0.2%)
Sep 2024
-
$425.44M(+17.4%)
$1.39B(+7.0%)
Jun 2024
-
$362.48M(+51.3%)
$1.30B(+3.6%)
Mar 2024
-
$239.59M(-33.7%)
$1.25B(-3.5%)
Dec 2023
$1.30B(-3.8%)
$361.43M(+7.9%)
$1.30B(+8.8%)
Sep 2023
-
$334.95M(+5.6%)
$1.19B(+2.5%)
Jun 2023
-
$317.21M(+11.5%)
$1.16B(-2.9%)
Mar 2023
-
$284.42M(+11.0%)
$1.20B(+1.5%)
Dec 2022
$1.35B(+41.8%)
$256.35M(-16.1%)
$1.18B(+0.4%)
Sep 2022
-
$305.68M(-13.1%)
$1.18B(+5.0%)
Jun 2022
-
$351.71M(+31.6%)
$1.12B(+14.8%)
Mar 2022
-
$267.26M(+6.1%)
$975.63M(+3.4%)
Dec 2021
$951.76M(-8.8%)
$251.80M(+1.0%)
$943.46M(-3.0%)
Sep 2021
-
$249.35M(+20.3%)
$972.75M(-2.8%)
Jun 2021
-
$207.22M(-11.9%)
$1.00B(-5.8%)
Mar 2021
-
$235.09M(-16.4%)
$1.06B(+1.8%)
Dec 2020
$1.04B(+3.1%)
$281.09M(+1.2%)
$1.04B(+4.2%)
Sep 2020
-
$277.70M(+3.3%)
$1.00B(+2.7%)
Jun 2020
-
$268.84M(+24.4%)
$975.85M(-0.3%)
Mar 2020
-
$216.09M(-9.7%)
$978.43M(-3.4%)
Dec 2019
$1.01B(+15.7%)
$239.19M(-5.0%)
$1.01B(+0.4%)
Sep 2019
-
$251.73M(-7.3%)
$1.01B(+1.2%)
Jun 2019
-
$271.41M(+8.5%)
$996.72M(+1.7%)
Mar 2019
-
$250.17M(+6.2%)
$980.10M(+12.1%)
Dec 2018
$874.97M(+12.3%)
$235.47M(-1.8%)
$874.47M(+3.5%)
Sep 2018
-
$239.67M(-5.9%)
$844.90M(+3.4%)
Jun 2018
-
$254.79M(+76.3%)
$817.06M(+7.7%)
Mar 2018
-
$144.54M(-29.8%)
$758.60M(-2.6%)
Dec 2017
$779.00M(+5.2%)
$205.91M(-2.8%)
$779.00M(+0.1%)
Sep 2017
-
$211.83M(+7.9%)
$778.36M(+4.1%)
Jun 2017
-
$196.32M(+19.0%)
$747.35M(-0.2%)
Mar 2017
-
$164.94M(-19.6%)
$749.02M(+1.3%)
Dec 2016
$740.68M(+14.0%)
$205.27M(+13.5%)
$739.16M(+5.7%)
Sep 2016
-
$180.83M(-8.7%)
$699.58M(+3.0%)
Jun 2016
-
$197.99M(+27.7%)
$678.96M(+2.8%)
Mar 2016
-
$155.08M(-6.4%)
$660.30M(+1.6%)
Dec 2015
$649.64M
$165.68M(+3.4%)
$649.79M(-0.8%)
Sep 2015
-
$160.21M(-10.7%)
$655.26M(-0.9%)
Jun 2015
-
$179.33M(+24.0%)
$660.88M(+5.5%)
DateAnnualQuarterlyTTM
Mar 2015
-
$144.58M(-15.5%)
$626.60M(+7.1%)
Dec 2014
$590.50M(+32.6%)
$171.14M(+3.2%)
$584.86M(+9.0%)
Sep 2014
-
$165.83M(+14.3%)
$536.42M(+8.0%)
Jun 2014
-
$145.05M(+41.1%)
$496.72M(+9.6%)
Mar 2014
-
$102.83M(-16.2%)
$453.34M(+1.5%)
Dec 2013
$445.30M(+40.3%)
$122.70M(-2.7%)
$446.84M(+3.8%)
Sep 2013
-
$126.13M(+24.0%)
$430.47M(+12.8%)
Jun 2013
-
$101.68M(+5.5%)
$381.66M(+15.2%)
Mar 2013
-
$96.33M(-9.4%)
$331.42M(+16.5%)
Dec 2012
$317.48M(+116.2%)
$106.33M(+37.5%)
$284.37M(+27.6%)
Sep 2012
-
$77.32M(+50.3%)
$222.88M(+19.1%)
Jun 2012
-
$51.44M(+4.4%)
$187.21M(+9.1%)
Mar 2012
-
$49.28M(+9.9%)
$171.59M(+16.8%)
Dec 2011
$146.86M(+120.8%)
$44.84M(+7.7%)
$146.88M(+13.3%)
Sep 2011
-
$41.65M(+16.2%)
$129.61M(+24.1%)
Jun 2011
-
$35.83M(+45.8%)
$104.46M(+28.2%)
Mar 2011
-
$24.57M(-10.9%)
$81.48M(+22.5%)
Dec 2010
$66.50M(+165.7%)
$27.57M(+67.2%)
$66.50M(+26.1%)
Sep 2010
-
$16.49M(+28.4%)
$52.72M(+24.5%)
Jun 2010
-
$12.85M(+34.0%)
$42.36M(+6.6%)
Mar 2010
-
$9.59M(-30.5%)
$39.73M(+58.8%)
Dec 2009
$25.03M(+120.5%)
$13.79M(+125.0%)
$25.03M(+750.2%)
Sep 2009
-
$6.13M(-40.0%)
-$3.85M(+88.6%)
Jun 2009
-
$10.22M(+299.7%)
-$33.65M(+60.9%)
Mar 2009
-
-$5.12M(+66.0%)
-$86.03M(+29.5%)
Dec 2008
-$122.08M(-34.7%)
-$15.08M(+36.3%)
-$122.08M(+14.6%)
Sep 2008
-
-$23.67M(+43.8%)
-$142.91M(-6.3%)
Jun 2008
-
-$42.16M(-2.4%)
-$134.41M(-17.0%)
Mar 2008
-
-$41.16M(-14.6%)
-$114.93M(-26.8%)
Dec 2007
-$90.62M(-33.8%)
-$35.91M(-136.6%)
-$90.62M(+45.4%)
Sep 2007
-
-$15.18M(+33.0%)
-$165.94M(-19.3%)
Jun 2007
-
-$22.67M(-34.5%)
-$139.09M(-32.8%)
Mar 2007
-
-$16.86M(+84.8%)
-$104.75M(-34.2%)
Dec 2006
-$67.74M(-31.0%)
-$111.23M(-1052.9%)
-$78.05M(-94.9%)
Sep 2006
-
$11.67M(0.0%)
-$40.04M(+13.6%)
Jun 2006
-
$11.67M(+18.7%)
-$46.35M(+12.0%)
Mar 2006
-
$9.84M(+113.4%)
-$52.67M(+7.8%)
Dec 2005
-$51.70M(-104.2%)
-$73.23M(-1465.9%)
-$57.14M(-455.3%)
Sep 2005
-
$5.36M(0.0%)
$16.08M(+50.0%)
Jun 2005
-
$5.36M(0.0%)
$10.72M(+100.0%)
Mar 2005
-
$5.36M
$5.36M
Dec 2004
-$25.32M
-
-

FAQ

  • What is Jazz Pharmaceuticals plc annual EBITDA?
  • What is the all-time high annual EBITDA for Jazz Pharmaceuticals plc?
  • What is Jazz Pharmaceuticals plc annual EBITDA year-on-year change?
  • What is Jazz Pharmaceuticals plc quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Jazz Pharmaceuticals plc?
  • What is Jazz Pharmaceuticals plc quarterly EBITDA year-on-year change?
  • What is Jazz Pharmaceuticals plc TTM EBITDA?
  • What is the all-time high TTM EBITDA for Jazz Pharmaceuticals plc?
  • What is Jazz Pharmaceuticals plc TTM EBITDA year-on-year change?

What is Jazz Pharmaceuticals plc annual EBITDA?

The current annual EBITDA of JAZZ is $1.39B

What is the all-time high annual EBITDA for Jazz Pharmaceuticals plc?

Jazz Pharmaceuticals plc all-time high annual EBITDA is $1.39B

What is Jazz Pharmaceuticals plc annual EBITDA year-on-year change?

Over the past year, JAZZ annual EBITDA has changed by +$88.72M (+6.84%)

What is Jazz Pharmaceuticals plc quarterly EBITDA?

The current quarterly EBITDA of JAZZ is $339.75M

What is the all-time high quarterly EBITDA for Jazz Pharmaceuticals plc?

Jazz Pharmaceuticals plc all-time high quarterly EBITDA is $425.44M

What is Jazz Pharmaceuticals plc quarterly EBITDA year-on-year change?

Over the past year, JAZZ quarterly EBITDA has changed by -$85.69M (-20.14%)

What is Jazz Pharmaceuticals plc TTM EBITDA?

The current TTM EBITDA of JAZZ is $1.20B

What is the all-time high TTM EBITDA for Jazz Pharmaceuticals plc?

Jazz Pharmaceuticals plc all-time high TTM EBITDA is $1.39B

What is Jazz Pharmaceuticals plc TTM EBITDA year-on-year change?

Over the past year, JAZZ TTM EBITDA has changed by -$188.03M (-13.54%)
On this page